Femasys names new chief commercial officer to drive execution and global growth

--new cco to lead u.s. commercialization of fertility products, including femaseed ® , and expand strategic global partnerships across full portfolio-- atlanta, june 17, 2025 (globe newswire) -- femasys, inc. (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of kelley nicholas as chief commercial officer (cco). ms. nicholas will be responsible for leading the execution and optimization of femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the u.s. infertility market and building key international partners.
FEMY Ratings Summary
FEMY Quant Ranking